Medical Oncology

Myelodysplastic Syndromes

Questions discussed in this category

How do you approach treatment for a patient with hypoplastic MDS who is not eligible for transplant?

What are non-clinical trial options to treat high-risk MDS in a transplant ineligible patient, after progression on hypomethylating agents?

2 Answers available

How do you diagnose MDS in a patient with equivocal morphological findings?

In the case of subtle single lineage dysplasia with normal cytogenetics, do you routinely perform NGS testing for CHIP-type clonal mutations? Do you ...

1 Answer available

How do you approach MDS patients with low/very low risk IPSS-R but high risk mutations on NGS?

Do next generation sequencing results influence diagnostic and therapeutic decisions for patients with MDS?

2 Answers available

Would you routinely use G-CSF prophylaxis in a CMML patient for decitabine-related neutropenia?

1 Answer available

How would you optimally manage a patient with a MDS/MPN overlap syndrome who has both transfusion-dependent anemia and marked thrombocytosis?

Would this change with someone who has a history of thrombosis (e.g. DVT/PE, MI, CVA)? Would this change with someone who is more fit vs more frail?

1 Answer available

Is there a role for frontline combination therapy with a hypomethylating agent plus venetoclax for high risk MDS?

1 Answer available

When do you utilize lenalidomide in patients with MDS without del(5q)?

Are there particular mutations (eg SF3B1) or syndromes (eg MDS/MPN overlaps such as MDS/MPN-RS-T) where you are more apt to using lenalidomide?

1 Answer available

Is there currently a role for adding venetoclax to a hypomethylating agent (HMA) after failure of single-agent HMA therapy in MDS?

Can results from emerging AML data be extrapolated to high risk MDS populations? Is there data to guide the choice of continuing the HMA in combinati...

1 Answer available

When would you use cedazuridine in combination with decitabine to treat intermediate or high risk MDS?

Given the recent FDA approval, how will the use of this oral combination fit into your practice? https://doi.org/10.1182/blood.2019004143

1 Answer available

Does isolated del(5q) have the same prognostic implications for post-PV secondary myelofibrosis as it does in MDS?

Given the rarity of this in MF, is it still predictive of response to lenalidomide therapy?

1 Answer available

What is your preferred first line treatment for patients with high risk MDS who are not candidates for transplant?

1 Answer available

What is the best strategy after initial treatment with hypomethylating agents for high grade myelodysplatic syndromes, mainly for responders who became transfusion independent?

Do we continue the hypomethylating agent indefinitely?

1 Answer available